Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.13
CBM's Cash to Debt is ranked lower than
77% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CBM: 1.13 )
Ranked among companies with meaningful Cash to Debt only.
CBM' s 10-Year Cash to Debt Range
Min: 0.01  Med: 0.24 Max: No Debt
Current: 1.13
Equity to Asset 0.51
CBM's Equity to Asset is ranked lower than
68% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CBM: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
CBM' s 10-Year Equity to Asset Range
Min: 0.22  Med: 0.44 Max: 0.74
Current: 0.51
0.22
0.74
F-Score: 8
Z-Score: 5.56
M-Score: -2.63
WACC vs ROIC
16.45%
29.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.19
CBM's Operating margin (%) is ranked higher than
85% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. CBM: 16.19 )
Ranked among companies with meaningful Operating margin (%) only.
CBM' s 10-Year Operating margin (%) Range
Min: -2.77  Med: 12.67 Max: 18.02
Current: 16.19
-2.77
18.02
Net-margin (%) 16.66
CBM's Net-margin (%) is ranked higher than
85% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. CBM: 16.66 )
Ranked among companies with meaningful Net-margin (%) only.
CBM' s 10-Year Net-margin (%) Range
Min: -98.33  Med: 6.31 Max: 82.87
Current: 16.66
-98.33
82.87
ROE (%) 27.33
CBM's ROE (%) is ranked higher than
95% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. CBM: 27.33 )
Ranked among companies with meaningful ROE (%) only.
CBM' s 10-Year ROE (%) Range
Min: -94.37  Med: 10.55 Max: 120.02
Current: 27.33
-94.37
120.02
ROA (%) 13.78
CBM's ROA (%) is ranked higher than
92% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. CBM: 13.78 )
Ranked among companies with meaningful ROA (%) only.
CBM' s 10-Year ROA (%) Range
Min: -37.93  Med: 3.72 Max: 42.71
Current: 13.78
-37.93
42.71
ROC (Joel Greenblatt) (%) 25.84
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CBM: 25.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1.19  Med: 13.11 Max: 33.06
Current: 25.84
-1.19
33.06
Revenue Growth (3Y)(%) 11.00
CBM's Revenue Growth (3Y)(%) is ranked higher than
67% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CBM: 11.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18  Med: 0.30 Max: 11
Current: 11
-18
11
EBITDA Growth (3Y)(%) 14.90
CBM's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CBM: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27  Med: -0.40 Max: 32.8
Current: 14.9
-27
32.8
EPS Growth (3Y)(%) 58.70
CBM's EPS Growth (3Y)(%) is ranked higher than
94% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CBM: 58.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBM' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.5  Med: 16.70 Max: 79.7
Current: 58.7
-21.5
79.7
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CBM Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
Chuck Royce 801,354 sh (-15.81%)
Jim Simons 328,200 sh (-30.25%)
» More
Q3 2014

CBM Guru Trades in Q3 2014

Chuck Royce 921,629 sh (+15.01%)
Jim Simons 261,500 sh (-20.32%)
» More
Q4 2014

CBM Guru Trades in Q4 2014

Joel Greenblatt 78,575 sh (New)
Paul Tudor Jones 17,728 sh (New)
Chuck Royce 956,112 sh (+3.74%)
Chuck Royce 956,112 sh (unchged)
Jim Simons 154,600 sh (-40.88%)
» More
Q1 2015

CBM Guru Trades in Q1 2015

Jim Simons 407,900 sh (+163.84%)
Paul Tudor Jones 43,435 sh (+145.01%)
Joel Greenblatt 60,855 sh (-22.55%)
Chuck Royce 569,112 sh (-40.48%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.80
CBM's P/E(ttm) is ranked higher than
72% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 40.90 vs. CBM: 21.80 )
Ranked among companies with meaningful P/E(ttm) only.
CBM' s 10-Year P/E(ttm) Range
Min: 1.05  Med: 15.21 Max: 63.2
Current: 21.8
1.05
63.2
Forward P/E 22.78
CBM's Forward P/E is ranked higher than
54% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. CBM: 22.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.60
CBM's PE(NRI) is ranked higher than
72% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 39.90 vs. CBM: 21.60 )
Ranked among companies with meaningful PE(NRI) only.
CBM' s 10-Year PE(NRI) Range
Min: 5.17  Med: 15.38 Max: 94.8
Current: 21.6
5.17
94.8
P/B 5.67
CBM's P/B is ranked lower than
57% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. CBM: 5.67 )
Ranked among companies with meaningful P/B only.
CBM' s 10-Year P/B Range
Min: 0.61  Med: 1.89 Max: 5.74
Current: 5.67
0.61
5.74
P/S 3.65
CBM's P/S is ranked higher than
79% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. CBM: 3.65 )
Ranked among companies with meaningful P/S only.
CBM' s 10-Year P/S Range
Min: 0.18  Med: 1.25 Max: 10.71
Current: 3.65
0.18
10.71
PFCF 29.89
CBM's PFCF is ranked higher than
63% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 41.97 vs. CBM: 29.89 )
Ranked among companies with meaningful PFCF only.
CBM' s 10-Year PFCF Range
Min: 4.81  Med: 14.15 Max: 245.33
Current: 29.89
4.81
245.33
POCF 18.75
CBM's POCF is ranked higher than
73% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. CBM: 18.75 )
Ranked among companies with meaningful POCF only.
CBM' s 10-Year POCF Range
Min: 2.94  Med: 10.07 Max: 65
Current: 18.75
2.94
65
EV-to-EBIT 22.04
CBM's EV-to-EBIT is ranked higher than
64% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. CBM: 22.04 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s 10-Year EV-to-EBIT Range
Min: -2271  Med: 11.10 Max: 388.4
Current: 22.04
-2271
388.4
PEG 1.96
CBM's PEG is ranked higher than
64% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.75 vs. CBM: 1.96 )
Ranked among companies with meaningful PEG only.
CBM' s 10-Year PEG Range
Min: 0.52  Med: 1.26 Max: 42.7
Current: 1.96
0.52
42.7
Shiller P/E 44.44
CBM's Shiller P/E is ranked higher than
55% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.44 vs. CBM: 44.44 )
Ranked among companies with meaningful Shiller P/E only.
CBM' s 10-Year Shiller P/E Range
Min: 5.64  Med: 30.94 Max: 141.6
Current: 44.44
5.64
141.6
Current Ratio 2.20
CBM's Current Ratio is ranked lower than
72% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. CBM: 2.20 )
Ranked among companies with meaningful Current Ratio only.
CBM' s 10-Year Current Ratio Range
Min: 0.9  Med: 2.54 Max: 5.19
Current: 2.2
0.9
5.19
Quick Ratio 1.18
CBM's Quick Ratio is ranked lower than
81% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CBM: 1.18 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s 10-Year Quick Ratio Range
Min: 0.5  Med: 1.42 Max: 4.55
Current: 1.18
0.5
4.55
Days Inventory 145.13
CBM's Days Inventory is ranked lower than
61% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. CBM: 145.13 )
Ranked among companies with meaningful Days Inventory only.
CBM' s 10-Year Days Inventory Range
Min: 107.67  Med: 132.76 Max: 228.78
Current: 145.13
107.67
228.78
Days Sales Outstanding 39.22
CBM's Days Sales Outstanding is ranked higher than
71% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. CBM: 39.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s 10-Year Days Sales Outstanding Range
Min: 49.84  Med: 58.63 Max: 112.79
Current: 39.22
49.84
112.79

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.14
CBM's Price/Tangible Book is ranked lower than
57% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. CBM: 7.14 )
Ranked among companies with meaningful Price/Tangible Book only.
CBM' s 10-Year Price/Tangible Book Range
Min: 1.63  Med: 3.66 Max: 14.41
Current: 7.14
1.63
14.41
Price/Projected FCF 3.05
CBM's Price/Projected FCF is ranked higher than
64% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. CBM: 3.05 )
Ranked among companies with meaningful Price/Projected FCF only.
CBM' s 10-Year Price/Projected FCF Range
Min: 0.83  Med: 2.14 Max: 12.66
Current: 3.05
0.83
12.66
Price/Median PS Value 2.92
CBM's Price/Median PS Value is ranked lower than
84% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. CBM: 2.92 )
Ranked among companies with meaningful Price/Median PS Value only.
CBM' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.15 Max: 7.42
Current: 2.92
0.21
7.42
Price/Peter Lynch Fair Value 1.59
CBM's Price/Peter Lynch Fair Value is ranked higher than
64% of the 50 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. CBM: 1.59 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56  Med: 1.21 Max: 8.25
Current: 1.59
0.56
8.25
Price/Graham Number 2.59
CBM's Price/Graham Number is ranked higher than
64% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CBM: 2.59 )
Ranked among companies with meaningful Price/Graham Number only.
CBM' s 10-Year Price/Graham Number Range
Min: 0.43  Med: 1.61 Max: 4.95
Current: 2.59
0.43
4.95
Earnings Yield (Greenblatt) (%) 4.50
CBM's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. CBM: 4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 8.20 Max: 222.1
Current: 4.5
0.3
222.1
Forward Rate of Return (Yacktman) (%) 15.15
CBM's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.58 vs. CBM: 15.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBM' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -42.4  Med: -7.90 Max: 21
Current: 15.15
-42.4
21

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XBX.Germany,
Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in a wide range of chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovator and generic drug companies. Products include APIs, pharmaceutical intermediates and, to a lesser extent, other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.
» More Articles for NYSE:CBM

Headlines

Articles On GuruFocus.com
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
7 Hot Growth Stocks that Have Outrun the Market in 1H15 - Analyst Blog Jul 02 2015
Can Cambrex Keep Profits Healthy On Gilead Pact? Jun 26 2015
Exact Sciences Corporation (EXAS) Falls: Stock Goes Down 5.5% - Tale of the Tape Jun 26 2015
Alder Biopharmaceuticals (ALDR) in Focus: Stock Falls 8.3% - Tale of the Tape Jun 26 2015
Will Cambrex (CBM) Continue to Surge Higher? - Tale of the Tape Jun 16 2015
WEEKEND VIDEO: 10 Growth Stocks in 10 Minutes Jun 07 2015
Cambrex Corporation Stock: 3 Reasons Why It Is a Top Choice for Growth Investors - Tale of the Tape Jun 03 2015
Coverage initiated on Cambrex by Singular Research May 29 2015
Cambrex To Present At The Jefferies 2015 Global Healthcare Conference May 27 2015
Cambrex To Present At The Jefferies 2015 Global Healthcare Conference May 27 2015
Cambrex To Present At UBS Global Healthcare Conference May 11 2015
Cambrex To Present At UBS Global Healthcare Conference May 11 2015
10-Q for Cambrex Corp. May 03 2015
Growth Names Pressured As IBD 50 Slumps 4% For Week May 01 2015
Cambrex Corp Earnings Call scheduled for 8:30 am ET today May 01 2015
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 01 2015
Cambrex posts 1Q profit May 01 2015
Cambrex posts 1Q profit May 01 2015
Cambrex Reports First Quarter 2015 Financial Results May 01 2015
Q1 2015 Cambrex Corp Earnings Release - Before Market Open May 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK